ATS2024: Gossamer Bio presented open label extension data for seralutinib, an inhibitor of PDGFR, CSF1R, and c-KIT, in PAH showing durability of effect at 72 weeks
- May 20, 2024
- 1 min read
CEO Faheem Hasnian and trial investigator Olivier Sitbon describe how some patients seem to not just be maintaining benefit, but improving at 72 weeks vs 24 weeks. Mr. Hasnian also recaps a transformative partnership with Chiesi that was announced earlier this month.
.png){kind=logo}